SELECT-AXIS 2 subgroup analysis. UPA demonstrated improved efficacy vs PBO at Wk 14 across all evaluated subgroups of pts with bDMARD-IR AS. No new safety signals. @XBaraliakos et al, Abs 0414 #ACR22 https://t.co/lTfm68XlEY https://t.co/PaWdrOljMO
Links:
Efficacy and Safety of Upadacitinib in Patients with Ankylosing Spondylitis wit…
http://ow.ly/YlLf50Lvugr
12-11-2022